Asher Bio Raises $108m For Immune Cell-Specific Therapies

Series B Follows $55m Series A Round In March

 
• By Mandy Jackson
  
Blue and green "venture capital" neon light
Asher Bio will use its funding to take lead program AB248 into the clinic • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business